AR018892A1 - Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis - Google Patents

Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis

Info

Publication number
AR018892A1
AR018892A1 ARP990102939A ARP990102939A AR018892A1 AR 018892 A1 AR018892 A1 AR 018892A1 AR P990102939 A ARP990102939 A AR P990102939A AR P990102939 A ARP990102939 A AR P990102939A AR 018892 A1 AR018892 A1 AR 018892A1
Authority
AR
Argentina
Prior art keywords
heteroaryl
cycloalkyl
alkyl
heterocycloalkylalkyl
cycloalkylalkyl
Prior art date
Application number
ARP990102939A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR018892A1 publication Critical patent/AR018892A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Se revelan compuestos aminotiazol carbono-sustituidos que tienen la formula (I) y las sales de los mismos aceptables farmacéuticamente. Lossustituyentes tienen los siguientes significados: R1 = R2, COR2, CONH2, CONR2R3, COOR3, o SO2R3; R2 = H, alquilo, cicloalquilo, heterocicloalquilo,cicloalquilalquilo, heterocicloalquilalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo; R3 = alquilo, cicloalquilo, heterocicloalquilo,cicloalquilalquilo, heterocicloalquilalquilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo; A = formula (II), en donde n = 0, 1, 2; m = 1, 2 perotanto n como m pueden ser 2, y X = O, NR12, S, o un enlace, o formula (III), en donde i, j = 0 o 1, pero no pueden ser ambos 1, e Y = alqueno sustituidoopcionalmente, alquilo, o cualesquiera de 2 átomos de carbono adyacentes de un anillo de cicloalquilo o cicloheteroalquilo de 3-7 átomos; R4 = alquilo,cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo, alquiloxicarbonilo, arilo, heteroarilo, arilalquilo, heteroarilalquilo,ariloxicarbonilo, o R9; R5, R6, R7, R8 = independientemente H, alquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo,arilo, heteroarilo, arilalquilo, heteroarilalquilo, halo, o hidroxi, alcoxi, amino NR16R17, tio o alquiltio con la condicion de que solamente uno detales grupos de heteroátomos está unido a cualquier átomo de carbon, o R5 = R6 = oxo, o R7 = R8 = oxo, cuando X = un enlace; R9 = formula (IV), en dondeZ = O, NR13,S; R10, R11 = independientemente H, alquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilo,heteroarilo, arilalquilo, heteroarilalquilo, halo, hidroxi, alcoxi, alquilcarboniloxi, carboxi, alquiloxicarbonilo, amino, NR14R15, carbamoílo, ureido, tio,o alquiltio; R12 = H, alquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilo, heteroarilo, arilalquilo,heteroarilalquilo, R13 = H, alquilo, cicloalquilo, heterocicloalquilo,cicloalquilalquilo, heterocicloalquilalquilo, arilo, heteroarilo, arilalquilo,
ARP990102939A 1998-06-18 1999-06-18 Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis AR018892A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8974798P 1998-06-18 1998-06-18

Publications (1)

Publication Number Publication Date
AR018892A1 true AR018892A1 (es) 2001-12-12

Family

ID=22219395

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102939A AR018892A1 (es) 1998-06-18 1999-06-18 Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis

Country Status (9)

Country Link
EP (1) EP1087951B9 (es)
JP (1) JP2002518380A (es)
AR (1) AR018892A1 (es)
AT (1) ATE288904T1 (es)
AU (1) AU768751B2 (es)
CA (1) CA2332325A1 (es)
DE (1) DE69923681T2 (es)
ES (1) ES2237919T4 (es)
WO (1) WO1999065884A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
ES2251395T3 (es) * 1999-07-26 2006-05-01 Banyu Pharmaceutical Co., Ltd. Derivados de biarilureas.
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
ATE309241T1 (de) * 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
AU2001230026A1 (en) * 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
AU2001252562A1 (en) * 2000-04-28 2001-11-12 Toshiharu Suzuki Medicinal compositions for suppressing beta-amyloid production
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
CN100457753C (zh) * 2000-07-26 2009-02-04 布里斯托尔-迈尔斯斯奎布公司 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
DE60117605T2 (de) 2000-12-21 2006-12-07 Bristol-Myers Squibb Co. Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
CA2735478C (en) * 2001-01-26 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
WO2002066035A2 (en) 2001-02-20 2002-08-29 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
EP1256578B1 (en) * 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
ES2255621T3 (es) * 2001-06-22 2006-07-01 MERCK & CO., INC. Inhibidores de tirosina quinasa.
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
EP1724270A3 (en) 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
EA200400707A1 (ru) 2001-11-22 2004-10-28 Биовитрум Аб Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
US20100098702A1 (en) 2008-09-16 2010-04-22 Longgui Wang Method of treating androgen independent prostate cancer
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US8748475B2 (en) 2004-01-12 2014-06-10 Natrogen Therapeutics International, Inc. Methods and compositions for treating lupus
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
ATE452896T1 (de) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
CA2533763C (en) 2003-08-01 2012-11-20 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-coa decarboxylase inhibitors
EP2208495B1 (en) 2003-08-01 2011-12-14 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors
WO2005011670A1 (en) 2003-08-01 2005-02-10 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
ATE400272T1 (de) 2003-08-01 2008-07-15 Chugai Pharmaceutical Co Ltd Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
WO2005016888A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
WO2006002829A1 (en) * 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Thiazolinone unsubstituted quinolines
US7601725B2 (en) 2004-07-16 2009-10-13 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as Aurora kinase inhibitors
JP2009521461A (ja) * 2005-12-22 2009-06-04 アイカジェン， インコーポレイテッド カルシウムチャネルアンタゴニスト
CA2636077C (en) 2006-01-18 2012-01-03 Amgen Inc. Thiazole compounds as protein kinase b (pkb) inhibitors
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
JPWO2008050600A1 (ja) * 2006-10-25 2010-02-25 株式会社ニュージェン・ファーマ 酸化ストレス性細胞死を分子背景とする難治性疾患の治療または予防剤
BRPI0811993A2 (pt) 2007-05-11 2014-11-18 Hoffmann La Roche " hetarilanilinas como moduladores para beta-amiloide ".
MX2009013869A (es) 2007-06-21 2010-03-17 Amgen Inc Proceso para hacer 2-amino-tiazolonas sustituidas.
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
KR101204213B1 (ko) 2007-12-21 2012-11-26 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 헤테로아릴 유도체
KR101244517B1 (ko) 2008-01-11 2013-03-18 에프. 호프만-라 로슈 아게 아밀로이드 베타에 대한 조절제
CA2713716A1 (en) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2010040661A1 (en) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
KR101293421B1 (ko) 2008-11-10 2013-08-05 에프. 호프만-라 로슈 아게 헤테로사이클릭 감마 분비효소 조절제
JPWO2010087313A1 (ja) * 2009-01-29 2012-08-02 株式会社林原生物化学研究所 神経突起伸展促進剤
WO2010087315A1 (ja) * 2009-01-29 2010-08-05 株式会社林原生物化学研究所 抗アルツハイマー病剤
JP5591720B2 (ja) * 2009-01-29 2014-09-17 株式会社林原 抗神経変性疾患剤
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
WO2014081925A1 (en) 2012-11-21 2014-05-30 Agios Pharmaceuticals, Inc. Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CN106231900B (zh) 2014-03-21 2019-05-28 阿吉奥斯制药公司 化合物及其使用方法
WO2017027984A1 (en) * 2015-08-20 2017-02-23 Simon Fraser University Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy
KR102130253B1 (ko) 2018-09-17 2020-07-03 영진약품 주식회사 신규한 티아졸 유도체 및 이의 약학적으로 허용가능한 염

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169954A (en) * 1962-08-06 1965-02-16 Eastman Kodak Co Monoazo thiazole dyestuffs
DE3418376A1 (de) * 1984-05-17 1985-11-21 Bayer Ag, 5090 Leverkusen Zwischenprodukte sowie verfahren zur herstellung von zwischenprodukten fuer die synthese von cephalosporinen
FR2612187B1 (fr) * 1987-03-12 1989-07-21 Sanofi Sa Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents

Also Published As

Publication number Publication date
DE69923681D1 (de) 2005-03-17
EP1087951B9 (en) 2006-09-13
AU768751B2 (en) 2004-01-08
EP1087951A4 (en) 2002-08-14
JP2002518380A (ja) 2002-06-25
EP1087951A1 (en) 2001-04-04
AU4431199A (en) 2000-01-05
DE69923681T2 (de) 2006-01-12
WO1999065884A1 (en) 1999-12-23
ES2237919T4 (es) 2007-05-01
CA2332325A1 (en) 1999-12-23
ES2237919T3 (es) 2005-08-01
ATE288904T1 (de) 2005-02-15
EP1087951B1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
AR018892A1 (es) Compuestos de aminotiazol carbono-sustituidos, utiles como inhibidores de quinasas dependientes de ciclinas y las composiciones farmaceuticas que lascontienen, metodo para el tratamiento de enfermedades proliferativas, inflamacion y artritis
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
CY1108445T1 (el) Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν
UY27918A1 (es) Derivados de benzodioxol
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
TW200526658A (en) Heterocyclic inhibitors of MEK and methods of use thereof
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
TN2011000380A1 (en) Triazolopyridine derivatives as p38 map kinase inhibitors
DE602005022284D1 (de) Substituierte benzimidazole und deren verwendung zur induktion von apoptose
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
PE20050336A1 (es) Compuestos triciclicos como inhibidores de la proteina farnesil transferasa
CO4980854A1 (es) Inhibidores de celulas b particularmente amidas, proceso par su produccion y composiciones farmaceuticas que los contiene
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
PE20040160A1 (es) 1,2-dihidropirazol-3-onas que controlan citoquinas inflamatorias
ECSP993012A (es) Inhibidores de aminotiazol substituidos con carbon de cianasa dependientes de la ciclina
BR0002514A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
AR126756A1 (es) Compuestos heterocíclicos y métodos de uso
UY28490A1 (es) Derivados de bencimidazol sustituidos con haloalquilo y piperidina
ECSP003505A (es) Derivados de 4-fenil- pirimidina